← Leaderboards
Ann C Duerr
Fred Hutchinson Cancer Research Center
$21,182,270
Attributed
$25,421,642
Total exposure
10
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.8M · FY2008–25$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$35,583,240 · 11
By mechanism
R01$21,989,592 · 5
U54$13,415,581 · 5
R03$178,067 · 1
Top collaborators
- Robinson Cabello24 shared
- Margaret M Madeleine24 shared
- Marie Marcelle H. Deschamps6 shared
- Yeycy A. Donastorg6 shared
- Nicolas Chomont4 shared
- Ying Qing Chen3 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Jonathan B Bricker$29,660,669
- Margaret M Madeleine$13,649,862
- Scott D Ramsey$15,774,676
- David F Penson$16,023,274
- Ruth D Etzioni$37,666,206
Others in their field
Top investigators on “Peru”
- Lawrence Corey · Fred Hutchinson Cancer Center$205,096,160
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$45,710,868
- Fred M Gordin · Social And Scientific Systems, Inc.$44,160,542
- Clarence Buddy Creech · Vanderbilt University Medical Center$43,087,946
- Robert M. Grant · J. David Gladstone Institutes$41,279,316
Research focus
PeruResponseIncidenceCaringAlgorithmsDoseLatin AmericaResourcesProtocols DocumentationDiagnosisVaccinationPersonsFutureSiteInfectionPreventionProgramsVaccinesWomanNovel StrategiesRegimenMortalityHiv InfectionsClinical Trials
Grant awards (55)
Identifying vulnerabilities in the long-lived HIV reservoir to accelerate its decay$958,175
R01 · FY2025 · AI · contact PI
Colaboración Evita: Cervical Cancer Prevention Partnership Center$689,186
U54 · FY2025 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$140,344
U54 · FY2025 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$124,182
U54 · FY2025 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$46,288
U54 · FY2025 · CA
Identifying vulnerabilities in the long-lived HIV reservoir to accelerate its decay$32,698
R01 · FY2025 · AI · contact PI
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$1,552,556
U54 · FY2024 · CA
Identifying vulnerabilities in the long-lived HIV reservoir to accelerate its decay$1,079,334
R01 · FY2024 · AI · contact PI
Project-002$360,646
U54 · FY2024 · CA
Project-001$266,150
U54 · FY2024 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$1,897,572
U54 · FY2023 · CA
Identifying vulnerabilities in the long-lived HIV reservoir to accelerate its decay$1,088,557
R01 · FY2023 · AI · contact PI
Project-002$475,984
U54 · FY2023 · CA
Project-001$234,732
U54 · FY2023 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$334,104
U54 · FY2022 · CA
Project-002$117,064
U54 · FY2022 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$1,000,000
U54 · FY2021 · CA
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$803,006
U54 · FY2021 · CA
Predicting PrEP Uptake and Adherence among Adolescent Girls and Young Women in Sub-Saharan Africa: Leveraging Programmatic and Clinical Trials Data$371,881
R01 · FY2021 · HD · contact PI
Project-001$226,643
U54 · FY2021 · CA
Project-002$215,903
U54 · FY2021 · CA
Project-001$165,385
U54 · FY2021 · CA
Project-002$159,204
U54 · FY2021 · CA
Predicting PrEP Uptake and Adherence among Adolescent Girls and Young Women in Sub-Saharan Africa: Leveraging Programmatic and Clinical Trials Data$118,787
R01 · FY2021 · HD · contact PI
Colaboracion Evita: HPV-Related Cancer Prevention Partnership Center$1,736,491
U54 · FY2020 · CA
Predicting PrEP Uptake and Adherence among Adolescent Girls and Young Women in Sub-Saharan Africa: Leveraging Programmatic and Clinical Trials Data$490,668
R01 · FY2020 · HD · contact PI
Project-001$427,763
U54 · FY2020 · CA
Project-002$150,690
U54 · FY2020 · CA
Cervical Cancer Prevention in Peru and the Dominican Republic$1,837,869
U54 · FY2019 · CA
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$1,458,040
R01 · FY2019 · DA · contact PI
Project-001$376,080
U54 · FY2019 · CA
Project-002$77,739
U54 · FY2019 · CA
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$39,177
R01 · FY2019 · DA · contact PI
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$1,744,166
R01 · FY2018 · DA · contact PI
Finding New Strategies for Achieving the UNAIDS 90-90-90 Targets: Cost-Effectiveness of a "Test and Treat" Intervention in Peru$76,487
R03 · FY2018 · AI · contact PI
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$1,844,857
R01 · FY2017 · DA · contact PI
Finding New Strategies for Achieving the UNAIDS 90-90-90 Targets: Cost-Effectiveness of a "Test and Treat" Intervention in Peru$101,580
R03 · FY2017 · AI · contact PI
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$94,399
R01 · FY2017 · DA · contact PI
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$16,588
R01 · FY2017 · DA · contact PI
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$1,715,614
R01 · FY2016 · DA · contact PI
Modulating the Impact of Critical Events in Early HIV Infection: Effect of Early ART Initiation and Alcohol Use$1,073,128
R01 · FY2015 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$968,494
R01 · FY2015 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$5,767
R01 · FY2015 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$1,273,480
R01 · FY2014 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$115,203
R01 · FY2014 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$9,166
R01 · FY2014 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$1,205,639
R01 · FY2013 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$107,999
R01 · FY2013 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$1,295,482
R01 · FY2012 · DA · contact PI
HIV Testing and Treatment to Prevent Onward HIV Transmission among High-risk MSM$1,615,108
R01 · FY2011 · DA · contact PI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity$421,014
R01 · FY2011 · DE · contact PI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity$523,120
R01 · FY2010 · DE · contact PI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity$1,005,250
R01 · FY2009 · DE · contact PI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity$462,658
R01 · FY2009 · DE · contact PI
Immunization of Oral Mucosa for Induction of Rectal and Genital Mucosal Immunity$855,143
R01 · FY2008 · DE · contact PI